110 related articles for article (PubMed ID: 34151904)
21. Mutations in the DNA polymerase binding pathway affect the immune microenvironment of patients with small-cell lung cancer and enhance the efficacy of platinum-based chemotherapy.
Lin A; Mou W; Zhu L; Yang T; Zhou C; Zhang J; Luo P
Cancer Innov; 2023 Dec; 2(6):500-512. PubMed ID: 38125769
[TBL] [Abstract][Full Text] [Related]
22. Small cell lung cancer (SCLC): no treatment advances in recent years.
Koinis F; Kotsakis A; Georgoulias V
Transl Lung Cancer Res; 2016 Feb; 5(1):39-50. PubMed ID: 26958492
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy advances in small-cell lung cancer.
Chan BA; Coward JI
J Thorac Dis; 2013 Oct; 5 Suppl 5(Suppl 5):S565-78. PubMed ID: 24163749
[TBL] [Abstract][Full Text] [Related]
24. Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer.
Bhamidipati D; Subbiah V
Oncoscience; 2023; 10():22-23. PubMed ID: 37324544
[No Abstract] [Full Text] [Related]
25. Author Correction: ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer.
Schultz CW; Zhang Y; Elmeskini R; Zimmermann A; Fu H; Murai Y; Wangsa D; Kumar S; Takahashi N; Atkinson D; Saha LK; Lee CF; Elenbaas B; Desai P; Sebastian R; Sharma AK; Abel M; Schroeder B; Krishnamurthy M; Bassel LL; Kumar R; Roper N; Aladjem M; Zenke FT; Ohler ZW; Pommier Y; Thomas A
EMBO Mol Med; 2024 Mar; 16(3):664. PubMed ID: 38366163
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.
Rajput PS; Khan SR; Singh P; Chawla PA
Anticancer Agents Med Chem; 2022; 22(5):812-820. PubMed ID: 34229593
[TBL] [Abstract][Full Text] [Related]
27. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
Das M; Padda SK; Weiss J; Owonikoko TK
Adv Ther; 2021 Nov; 38(11):5431-5451. PubMed ID: 34564806
[TBL] [Abstract][Full Text] [Related]
28. Editorial: Small cell lung cancer: New drugs and strategies.
Cortinovis DL; Morabito A
Front Med (Lausanne); 2023; 10():1140642. PubMed ID: 36778741
[No Abstract] [Full Text] [Related]
29. Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
Petty WJ; Paz-Ares L
JAMA Oncol; 2023 Mar; 9(3):419-429. PubMed ID: 36520421
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy era in the treatment of small cell lung cancer.
Araz M; Karakurt Eryilmaz M
Med Oncol; 2021 Jun; 38(7):86. PubMed ID: 34156575
[TBL] [Abstract][Full Text] [Related]
31. Small Cell Lung Carcinoma: Current Diagnosis, Biomarkers, and Treatment Options with Future Perspectives.
Krpina K; Vranić S; Tomić K; Samaržija M; Batičić L
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509621
[TBL] [Abstract][Full Text] [Related]
32. Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade.
Oliver J; Onieva JL; Garrido-Barros M; Cobo-Dols M; Martínez-Gálvez B; García-Pelícano AI; Dubbelman J; Benítez JC; Martín JZ; Cantero A; Pérez-Ruiz E; Rueda-Domínguez A; Barragán I
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444467
[TBL] [Abstract][Full Text] [Related]
33. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Aix SP; Ciuleanu TE; Navarro A; Cousin S; Bonanno L; Smit EF; Chiappori A; Olmedo ME; Horvath I; Grohé C; Farago AF; López-Vilariño JA; Cullell-Young M; Nieto A; Vasco N; Gómez J; Kahatt C; Zeaiter A; Carcereny E; Roubec J; Syrigos K; Lo G; Barneto I; Pope A; Sánchez A; Kattan J; Zarogoulidis K; Waller CF; Bischoff H; Juan-Vidal O; Reinmuth N; Dómine M; Paz-Ares L
Lancet Respir Med; 2023 Jan; 11(1):74-86. PubMed ID: 36252599
[TBL] [Abstract][Full Text] [Related]
34. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
[TBL] [Abstract][Full Text] [Related]
35. Lurbinectedin for small cell lung cancer.
Aust Prescr; 2022 Feb; 45(1):31. PubMed ID: 35233139
[No Abstract] [Full Text] [Related]
36. Recent developments in the treatment of small cell lung cancer.
Hiddinga BI; Raskin J; Janssens A; Pauwels P; Van Meerbeeck JP
Eur Respir Rev; 2021 Sep; 30(161):. PubMed ID: 34261744
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy in small cell lung cancer: one step at a time: a narrative review.
Dumoulin DW; Dingemans AC; Aerts JGJV; Remon J; De Ruysscher DKM; Hendriks LEL
Transl Lung Cancer Res; 2021 Jun; 10(6):2970-2987. PubMed ID: 34295691
[TBL] [Abstract][Full Text] [Related]
38. Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy.
Wang Y; Mathai J; Alamgeer M; Parakh S; Paul E; Mitchell P; Arulananda S
JTO Clin Res Rep; 2023 Aug; 4(8):100544. PubMed ID: 37529402
[TBL] [Abstract][Full Text] [Related]
39. A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study.
Fudio S; Pérez-Ramos L; Asín-Prieto E; Zeaiter A; Lubomirov R
Front Oncol; 2023; 13():1152371. PubMed ID: 37397388
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
